GLP-1R
11 drugs Metabolic
3
approved indications
11
Approved Drugs
5
Companies
14
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (5 companies)
✓ All 11 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (14 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Novo Nordisk 6 drugs
SANOFI-AVENTIS US 2 drugs
Eli Lilly 1 drug
By Therapeutic Area
Other 6 drugs
Metabolic 5 drugs
Drugs by Company PRO
SANOFI-AVENTIS US 2 drugs
Eli Lilly 1 drug
ORBICULAR 1 drug
AMYLIN 1 drug
By Therapeutic Area
Other 6 drugs
TRULICITY, SAXENDA, RYBELSUS, VICTOZA +2 more
Metabolic 5 drugs
OZEMPIC, XULTOPHY 100/3.6, SOLIQUA 100/33, ADLYXIN +1 more
Indications Treated
Glycemic control in adults with type 2 diabetes mellitusGlycemic control in pediatric patients 10 years of age and older with type 2 diabetes mellitusReduction of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factorsType 2 DiabetesImprovement of glycemic control in adults with type 2 diabetes mellitusReduction in the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus at high risk for these eventsType 2 diabetes mellitusObesity in adultsObesity in pediatric patients aged 12 years and older with body weight greater than 60 kgOverweight in adults in the presence of at least one weight-related comorbid conditionType 2 diabetes mellitus (glycemic control in patients 10 years and older)Major adverse cardiovascular events risk reduction (adults with type 2 diabetes mellitus and established cardiovascular disease)Cardiovascular DiseaseDiabetic Ketoacidosis
All Drugs Targeting GLP-1R
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| TRULICITY | Eli Lilly | 2014 | 3 | |
| SAXENDA | Novo Nordisk | 2014 | 3 | |
| RYBELSUS | Novo Nordisk | 2019 | 2 | |
| VICTOZA | Novo Nordisk | 2010 | 2 | |
| OZEMPIC | Novo Nordisk | 2017 | 2 | Metabolic |
| XULTOPHY 100/3.6 | Novo Nordisk | 2016 | 2 | Metabolic |
| SOLIQUA 100/33 | SANOFI-AVENTIS US | 2016 | 2 | Metabolic |
| ADLYXIN | SANOFI-AVENTIS US | 2016 | 2 | Metabolic |
| LIRAGLUTIDE | ORBICULAR | 2024 | 1 | Metabolic |
| BYETTA | AMYLIN | 2005 | 1 | |
| WEGOVY | Novo Nordisk | 2021 | - |